Thorsten H. Ecke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Thorsten H. Ecke has a total of 248 co-authors. Here are the top co-authors by number of shared publications:
- Holger Gerullis
University Hospital for Urology, Klinikum Oldenburg, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Germany
9 shared publications Stefan Koch
Institute of Pathology, Brandenburg Medical School, Brandenburg, Germany
8 shared publications- Anja Rabien
Department of Urology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
7 shared publications Steffen Hallmann
Department of Urology, HELIOS Hospital, Bad Saarow, Germany
6 shared publications- Dimitri Barski
Department of Urology, Lukas Hospital Neuss, Germany
5 shared publications - Florence Le Calvez-Kelm
Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
5 shared publications
Latest Publications
- Open Access
- 9 July 2026
- Published by Wiley in Cancer Cytopathology
- Vol. 134 (8) , e70130
Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real‐world cohort
Background: Urine cytology is recommended for noninvasive detection of urothelial carcinoma (UC) but shows limited sensitivity, particularly in low‐grade disease. Keratin 17 (K17) has emerged as a promising immunocytochemical marker. This study evaluated the diagnostic performance and interobserver agreement of K17 in a routine setting. Methods: This prospective cross‐sectional study included 184 urine samples from patients undergoing diagnostic evaluation for suspected UC. K17 immunocytochemistry was performed with a fully automated platform and independently evaluated by two blinded raters. Cytology was classified according to The Paris System for Reporting Urinary Cytology. UC status was determined by histology when available or by follow‐up and multidisciplinary assessment. Diagnostic accuracy was assessed by receiver operating characteristic (ROC) analysis; interobserver reliability was assessed with the Cohen κ and intraclass correlation coefficient (ICC). Multivariable logistic regression evaluated combined diagnostic approaches. Results: K17 expression was significantly higher in UC than in non‐UC samples ( p < .001). Across raters, area under the ROC curve (AUC) values ranged from 0.68 to 0.71. Sensitivity was 52.9%–65.9%, with a specificity of 73.7%–82.8%. Sensitivity ranged from 45.5% to 54.5% for low‐grade tumors and from 57.7% to 73.1% for high‐grade tumors. In stage‐based analyses, sensitivity was 49.2%–61.5% for non–muscle‐invasive UC and 65%–80% for muscle‐invasive UC. Combining K17 with cytology numerically improved diagnostic discrimination (AUC value, 0.76; 95% CI, 0.69–0.83). Interobserver agreement was moderate to substantial (κ = 0.684; ICC, 0.653). Limitations included single‐center design, partial histological verification (81%), and post hoc optimized cutoffs. Conclusions: K17 immunocytochemistry is a reproducible adjunct to urine cytology, with moderate diagnostic performance. It may warrant further evaluation as an adjunctive marker, particularly in low‐grade and cytologically equivocal cases.
- 9 July 2026
- Published by Wiley in Cancer Cytopathology
- Vol. 134 (8) , e70130
Open AccessKeratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real‐world cohort
Background: Urine cytology is recommended for noninvasive detection of urothelial carcinoma (UC) but shows limited sensitivity, particularly in low‐grade disease. Keratin 17 (K17) has emerged as a promising immunocytochemical marker. This study evaluated the diagnostic performance and interobserver agreement of K17 in a routine setting. Methods: This prospective cross‐sectional study included 184 urine samples from patients undergoing diagnostic evaluation for suspected UC. K17 immunocytochemistry was performed with a fully automated platform and independently evaluated by two blinded raters. Cytology was classified according to The Paris System for Reporting Urinary Cytology. UC status was determined by histology when available or by follow‐up and multidisciplinary assessment. Diagnostic accuracy was assessed by receiver operating characteristic (ROC) analysis; interobserver reliability was assessed with the Cohen κ and intraclass correlation coefficient (ICC). Multivariable logistic regression evaluated combined diagnostic approaches. Results: K17 expression was significantly higher in UC than in non‐UC samples ( p < .001). Across raters, area under the ROC curve (AUC) values ranged from 0.68 to 0.71. Sensitivity was 52.9%–65.9%, with a specificity of 73.7%–82.8%. Sensitivity ranged from 45.5% to 54.5% for low‐grade tumors and from 57.7% to 73.1% for high‐grade tumors. In stage‐based analyses, sensitivity was 49.2%–61.5% for non–muscle‐invasive UC and 65%–80% for muscle‐invasive UC. Combining K17 with cytology numerically improved diagnostic discrimination (AUC value, 0.76; 95% CI, 0.69–0.83). Interobserver agreement was moderate to substantial (κ = 0.684; ICC, 0.653). Limitations included single‐center design, partial histological verification (81%), and post hoc optimized cutoffs. Conclusions: K17 immunocytochemistry is a reproducible adjunct to urine cytology, with moderate diagnostic performance. It may warrant further evaluation as an adjunctive marker, particularly in low‐grade and cytologically equivocal cases.
- 1 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (4) , 102554
Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology
- 1 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (4) , 102554
Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology
- 24 February 2026
- Published by Springer Nature in Die Urologie
- Vol. 65 (6) , 647-649
Bericht über die 16. Jahrestagung des Deutschen Forschungsverbundes Blasenkarzinom e. V. (DFBK) am 16. und 17. Januar 2026 in Ulm
- 24 February 2026
- Published by Springer Nature in Die Urologie
- Vol. 65 (6) , 647-649
Bericht über die 16. Jahrestagung des Deutschen Forschungsverbundes Blasenkarzinom e. V. (DFBK) am 16. und 17. Januar 2026 in Ulm
- Open Access
- 18 December 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (12)
Urinary biomarkers in multicentric studies: Shaping the future of bladder cancer diagnosis and follow‐up
Background and Objective: Bladder cancer (BC), a prevalent malignancy, poses significant diagnostic and surveillance challenges due to its high recurrence rates and reliance on cystoscopy, an invasive procedure for diagnosis and monitoring. While urine‐based genomic and proteomic biomarkers offer promising non‐invasive alternatives, their clinical implementation remains limited. This review synthesizes evidence from multicentric studies on urinary biomarkers for BC and evaluates their potential in reducing unnecessary invasive cystoscopies. Methods: A comprehensive review of literature was conducted searching for multicentric studies on urine‐based genomic and proteomic biomarkers for BC detection and/or surveillance. MEDLINE/Pubmed, Embase and Scopus databases and BJUI, UroToday and European Urology Oncology registries were searched using National Library of Medicine Medical Subject Headings (MeSH) terms. Emphasis was placed on the comparative performance of diagnostic platforms across different research and clinical settings. Key Findings and Limitations: The literature search yielded 51 reports that were included for analysis. Multicentre studies enhance the generalizability of findings by addressing inter‐laboratory variability and population diversity. This review underscores the importance of standardization, comparative performance analyses that these studies provide, and the potential for cost‐effective non‐invasive diagnostic tools. However, despite FDA approvals, no biomarker has replaced cystoscopy in clinical settings due to an inconsistent and insufficient combination of sensitivity, specificity and cost‐effectiveness parameters. The performance of AssureMDX and Enhanced CxBladder tests showed the most promise, but further large‐scale, standardized validation is still necessary. Conclusions and Clinical Implications: Urine‐based biomarkers have the potential to improve early BC detection and surveillance while reducing reliance on invasive procedures and costs related to the disease. Future efforts should prioritize cost‐effective, large‐scale multicentric studies to facilitate the adoption of these biomarkers into routine practice.
- 18 December 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (12)
Open AccessUrinary biomarkers in multicentric studies: Shaping the future of bladder cancer diagnosis and follow‐up
Background and Objective: Bladder cancer (BC), a prevalent malignancy, poses significant diagnostic and surveillance challenges due to its high recurrence rates and reliance on cystoscopy, an invasive procedure for diagnosis and monitoring. While urine‐based genomic and proteomic biomarkers offer promising non‐invasive alternatives, their clinical implementation remains limited. This review synthesizes evidence from multicentric studies on urinary biomarkers for BC and evaluates their potential in reducing unnecessary invasive cystoscopies. Methods: A comprehensive review of literature was conducted searching for multicentric studies on urine‐based genomic and proteomic biomarkers for BC detection and/or surveillance. MEDLINE/Pubmed, Embase and Scopus databases and BJUI, UroToday and European Urology Oncology registries were searched using National Library of Medicine Medical Subject Headings (MeSH) terms. Emphasis was placed on the comparative performance of diagnostic platforms across different research and clinical settings. Key Findings and Limitations: The literature search yielded 51 reports that were included for analysis. Multicentre studies enhance the generalizability of findings by addressing inter‐laboratory variability and population diversity. This review underscores the importance of standardization, comparative performance analyses that these studies provide, and the potential for cost‐effective non‐invasive diagnostic tools. However, despite FDA approvals, no biomarker has replaced cystoscopy in clinical settings due to an inconsistent and insufficient combination of sensitivity, specificity and cost‐effectiveness parameters. The performance of AssureMDX and Enhanced CxBladder tests showed the most promise, but further large‐scale, standardized validation is still necessary. Conclusions and Clinical Implications: Urine‐based biomarkers have the potential to improve early BC detection and surveillance while reducing reliance on invasive procedures and costs related to the disease. Future efforts should prioritize cost‐effective, large‐scale multicentric studies to facilitate the adoption of these biomarkers into routine practice.
- Open Access
Differential Androgen Receptor Expression Across Bladder Cancer Stages and Its Link to Poor Outcomes
Urinary bladder cancer is the tenth most common malignancy worldwide and represents a major global health burden
Open AccessDifferential Androgen Receptor Expression Across Bladder Cancer Stages and Its Link to Poor Outcomes
Urinary bladder cancer is the tenth most common malignancy worldwide and represents a major global health burden
- Open Access
- 22 October 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (11) , 1134
Role of Vaginal Microbiota and Oral Lactobacillus Supplementation in Recurrent Urinary Tract Infections of Menopausal Women: Protocol for the VaMirUTI Cohort Study
(1) Background: Recurrent urinary tract infections (rUTIs) are common among peri- and postmenopausal women, partly due to hormonal changes that disrupt the vaginal microbiota. A reduction in Lactobacillus dominance is associated with increased risk of rUTI. Although antibiotics remain the standard of care, their use contributes to the emergence of multidrug-resistant pathogens. Probiotics may offer a non-antibiotic alternative; however, clinical evidence remains limited. (2) Methods: The VaMirUTI study is a prospective, monocentric, non-randomized cohort investigating the combined effect of oral probiotics and vaginal estriol on vaginal and urinary microbiota in peri- and postmenopausal women with recurrent UTIs. The primary endpoints are (i) change in Lactobacillus dominance at 3 months and (ii) UTI recurrence at 12 months. A total of 100 women (70 rUTI, 30 controls) will be followed for up to 12 months. Vaginal swabs and urine samples will be collected at baseline, during UTI episodes, and at study completion. Vaginal microbiota composition will be analyzed by 16S rRNA gene sequencing. (3) Results: This protocol outlines the study design and methodology. The primary outcome is the change in vaginal Lactobacillus dominance following the intervention. Secondary outcomes include UTI recurrence rates and the identification of microbiota signatures associated with rUTI. (4) Conclusions: The VaMirUTI study will clarify the relationship between vaginal microbiota, oral probiotic supplementation, and rUTI in menopausal women, potentially informing future non-antibiotic preventive strategies.
- 22 October 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (11) , 1134
Open AccessRole of Vaginal Microbiota and Oral Lactobacillus Supplementation in Recurrent Urinary Tract Infections of Menopausal Women: Protocol for the VaMirUTI Cohort Study
(1) Background: Recurrent urinary tract infections (rUTIs) are common among peri- and postmenopausal women, partly due to hormonal changes that disrupt the vaginal microbiota. A reduction in Lactobacillus dominance is associated with increased risk of rUTI. Although antibiotics remain the standard of care, their use contributes to the emergence of multidrug-resistant pathogens. Probiotics may offer a non-antibiotic alternative; however, clinical evidence remains limited. (2) Methods: The VaMirUTI study is a prospective, monocentric, non-randomized cohort investigating the combined effect of oral probiotics and vaginal estriol on vaginal and urinary microbiota in peri- and postmenopausal women with recurrent UTIs. The primary endpoints are (i) change in Lactobacillus dominance at 3 months and (ii) UTI recurrence at 12 months. A total of 100 women (70 rUTI, 30 controls) will be followed for up to 12 months. Vaginal swabs and urine samples will be collected at baseline, during UTI episodes, and at study completion. Vaginal microbiota composition will be analyzed by 16S rRNA gene sequencing. (3) Results: This protocol outlines the study design and methodology. The primary outcome is the change in vaginal Lactobacillus dominance following the intervention. Secondary outcomes include UTI recurrence rates and the identification of microbiota signatures associated with rUTI. (4) Conclusions: The VaMirUTI study will clarify the relationship between vaginal microbiota, oral probiotic supplementation, and rUTI in menopausal women, potentially informing future non-antibiotic preventive strategies.
- 19 August 2025
- Published by Springer Nature in Nature Reviews Urology
- Vol. 23 (1) , 40-49
Urinary bladder cancer needs more attention — recommendations for health care professionals and politicians in the European Union
Cancer is a crucial health priority of the current European Commission and a pillar of a strong European Health Union. However, policy measures targeting cancer in the EU do not approach all types of cancer equally. Bladder cancer is the fifth most common cancer in Europe. Although bladder cancer is associated with one of the highest lifetime costs of any cancer, research funding is among the lowest. This imbalance has led to an alarming stagnation in the availability of diagnostic tools, which negatively affected the prognosis and treatment options for bladder cancer, and resulted in complex pathways for patients. The lack of bladder-cancer awareness drastically hinders early detection. Furthermore, insufficient understanding of gender differences in bladder-cancer symptoms exacerbates the gender gap, leading to worse outcomes for women. After the European elections in 2024 and the learnings from Europe’s Beating Cancer Plan, additional effort is needed to inform the policymakers in Brussels and the Member-State capitals to consider an EU agenda with ambitious policy actions targeting neglected cancers, such as bladder cancer, and close the cancer-care gap by supporting awareness and education and by ensuring access to high-quality diagnostic tools, care and treatment.
- 19 August 2025
- Published by Springer Nature in Nature Reviews Urology
- Vol. 23 (1) , 40-49
Urinary bladder cancer needs more attention — recommendations for health care professionals and politicians in the European Union
Cancer is a crucial health priority of the current European Commission and a pillar of a strong European Health Union. However, policy measures targeting cancer in the EU do not approach all types of cancer equally. Bladder cancer is the fifth most common cancer in Europe. Although bladder cancer is associated with one of the highest lifetime costs of any cancer, research funding is among the lowest. This imbalance has led to an alarming stagnation in the availability of diagnostic tools, which negatively affected the prognosis and treatment options for bladder cancer, and resulted in complex pathways for patients. The lack of bladder-cancer awareness drastically hinders early detection. Furthermore, insufficient understanding of gender differences in bladder-cancer symptoms exacerbates the gender gap, leading to worse outcomes for women. After the European elections in 2024 and the learnings from Europe’s Beating Cancer Plan, additional effort is needed to inform the policymakers in Brussels and the Member-State capitals to consider an EU agenda with ambitious policy actions targeting neglected cancers, such as bladder cancer, and close the cancer-care gap by supporting awareness and education and by ensuring access to high-quality diagnostic tools, care and treatment.
- 21 May 2025
- Published by Springer Nature in Die Urologie
- Vol. 64 (7) , 713-714
Früherkennungsmaßnahmen beim Urothelkarzinom des oberen und unteren Harntrakts sinnvoll einsetzen – kritische Bewertung von urinbasierten Schnelltests
- 21 May 2025
- Published by Springer Nature in Die Urologie
- Vol. 64 (7) , 713-714
Früherkennungsmaßnahmen beim Urothelkarzinom des oberen und unteren Harntrakts sinnvoll einsetzen – kritische Bewertung von urinbasierten Schnelltests
- 5 March 2025
- Published by Springer Nature in Die Urologie
- Vol. 64 (5) , 476-478
Bericht über die 15. Jahrestagung des Deutschen Forschungsverbundes Blasenkarzinom e. V. (DFBK) am 24. und 25. Januar 2025 in Jena
- 5 March 2025
- Published by Springer Nature in Die Urologie
- Vol. 64 (5) , 476-478
Bericht über die 15. Jahrestagung des Deutschen Forschungsverbundes Blasenkarzinom e. V. (DFBK) am 24. und 25. Januar 2025 in Jena
- 20 February 2025
- Published by Elsevier in European Urology
- Vol. 87 (5) , 504-506
Why We Need More Attention on Bladder Cancer: Establishing Policy Recommendations for Health Care Professionals and Politicians
- 20 February 2025
- Published by Elsevier in European Urology
- Vol. 87 (5) , 504-506
Why We Need More Attention on Bladder Cancer: Establishing Policy Recommendations for Health Care Professionals and Politicians